Introduction: Deposition of aerosolized medications from an in-line small volume nebulizer (SVN) has been shown to be dependent on a number of factors including flowrate, nebulizer position in the circuit, and inspiratory to expiratory ratio (I:E) on a mechanical ventilator. In addition to these factors constant flow (bias flow) through the circuit also affects optimal delivery. We hypothesized that isolating medication delivery from ventilator circuit using an enhancement device (ED) can significantly improve delivery of aerosolized medication.
Setup: Our enhancement device consists of a one way reservoir loop attached at the wye of the ventilator circuit using a female to female connector. This loop consists of a one way valve into the nebulizer T-piece. This is followed by 150 ml corrugated tubing (1-inch diameter) which acts as a reservoir. This reservoir connects to a patient T-piece connector with a one-way valve out in the connection to the other end of the wye loop.
Methods: We
used a Michigan lung model with two filters positioned 200cc?s (24inches) from
the wye. The lung compliance was set at 30cm H2O. The model was ventilated sequentially
with two volume ventilators, TBird AVS and Bear 1000tes. Bias Flow was set at
10 L/M. Each ventilator was set on A/C, RR 15, Vt 500 cc, FiO2 21%, PEEP +5
cmH2O at I:E ratios 1:3 and 1:6. Location of the nebulizer port on the inspiratory
side of the ventilator circuit was varied between 50cc?s, 100cc?s, and 150cc?s
prior to wye. At each location SVNs were administered with 3mls of .5mg/ml albuterol
at 7L/M for 15 minutes and samples were collected. SVNs were then administered
through the nebulizer port of the enhancement device and samples were collected.
The samples (filters with absorbed medication) were removed from the circuit
following each nebulization and dissolved in 8mls of 70% ethanol in a sterile
container. The filters remained in ethanol for approximately 8 hours. A sample
of 0.7mls from each container was then analyzed using a spectrophotometer at
278 nanometers. The optical densities of each sample were then plotted on a
graph of known albuterol concentrations to convert the data to mg albuterol/ml.
and results were compared.
Results:
| VENT SET. A/C f-15 B/M, 21%, 500ml, PEEP 5 | Nebulizer attached 50ml prior to prox. airway | Nebulizer attached 100ml prior to prox. airway | Nebulizer attached 150ml prior to prox. airway | Nebulizer attached to the neb port in Enhancement. Device (ED) |
|
I:E Ratio: 1:3 Flow: 40-42 L/M |
Mean:
.757 SD:0.193 Range: .581-1.012 Deposit: 0.10mg/ml Deposit: 5.3% |
Mean:
1.043 SD: 0.120 Range: .887-1.161 Deposit: 0.155mg/ml Deposit: 8.3% |
Mean:
1.164 SD: 0.260 Range: .892-1.403 Deposit: 0.18mg/ml Deposit: 9.6% |
Mean:
1.642 SD: 0.497 Range1.019-2.224 Deposit: 0.30mg/ml Deposit: 16% |
|
I:E Ratio: 1:6 Flow: 72-78L/M |
Mean:0.572 SD: 0.087 Range: 0.444-.638 Deposit: .073mg/ml Deposit: 3.9% |
Mean:0.673 SD: 0.181 Range: 0.443-.865 Deposit: 0.09mg/ml Deposit: 4.8% |
Mean:
0.776 SD: 0.118 Range: 0.667-.912 Deposit: 0.107mg/ml Deposit: 5.7%
|
Mean:.1.384 SD: 0.145 Range:1.176-1.506 Deposit: 0.23mg/ml Deposit: 12.3% |
Discussion: Our data suggest that the delivery of nebulized medications can be significantly increased on any ventilator settings by attaching the in-line small volume nebulizer to the enhancement device. We believe that use of this device would enhance the care of mechanically ventilated asthmatics, often requiring short inspiratory times and prolonged expiratory time.
OF-02-107